Orbits Oncology

ORGANOID PHENOTYPING PLATFORM

health AI/biotech focused on organoid phenotyping for oncology

Visit website LinkedIn ↗

StageFunded

YC batchCohort 2023

Founded2023

Employees7

LocationSan Francisco, CA

Business modelB2B SaaS

About

Orbits Oncology is bringing patient insights into the heart of early cancer drug development and personalized medicine. We transform patient tumor data into digital patient surrogates to help cancer researchers make better decisions in drug development and de-risk translation into the clinic. We offer an automated AI software platform for cancer researchers using live-cell imaging techniques to rapidly transform your microscope images into clear analysis reports and graphs with patient-relevant meaning. Whether it is research into drug development, therapy screening, personalized medicine or more, we provide customized platform solutions for your research pipeline so you can accelerate your preclinical and clinical developments.

Product

Value proposition: Automated quantitative readouts from live-cell imaging of organoids, spheroids, and other complex in vitro models, with scalable, multi-modality analysis and routed workflows for team sharing.
Target customers: Biotech and pharma companies, contract research organizations, academic research labs

Founders

Abraham Lin — CEO
Rebecca Stone — Founder
Tyler Gilcrest — Founder
Christophe Deben — Founder
Maxim Le Compte — Founder

Products

Organoid phenotyping platform (image analysis, quantification, workflow integration)Platform for image upload, segmentation, quantification, dynamic readouts, and sharing

Key features

Image-to-insight workflow for organoids and other 3D modelsAutomated quantitative readouts from raw imagesMulti-modality analysis in unified workflowCompatibility with live-cell imaging systemsScale across plates, conditions, and timepointsEvolutionary metrics: growth, death, morphology, kineticsExport of analysis-ready results and reportsIndustry-grade platform with shared team access

Technologies

AI image analysislive-cell imagingbrightfield and fluorescence workflowsorganoid segmentationphenotype quantification3D in vitro modeling

Integrations

Imaging systems (live-cell/high-content imagers)

Target conditions

cancertumor organoidsdrug screeningtoxicologyfunctional assays

Care settings

labresearch centerbiotech/biopharma R&D labs

Traction metrics

Investors

MDS Studio

News

Orbits Oncology - Creative Destruction Lab · 2025-06-19T02:09:37.000Z
Orbits Oncology - ai #pgh #precisionmedicine #startups - LinkedIn · 2025-09-23T00:00:00.000Z
Orbits Oncology Joins Plug and Play Lifetech Accelerator - LinkedIn · 2026-03-24T00:00:00.000Z
#cancer #biopharma #drugdiscovery #precisionmedicine #organoids #digitalplatform #ai #lifescience | Orbits Oncology · 2024-08-12T21:30:27.000Z
BioOrbit Raises £9.8M Seed To Manufacture Cancer Drugs in Orbit · 2026-05-01T04:20:00.000Z
Orbit Genomics, Inc. was awarded a two-year, $2million Direct to Phase II SBIR Grant from NIH/NCI to develop a subtyping lung cancer blood test – Orbit Genomics · 2024-09-23T00:00:00.000Z

Browse similar startups

Related startups

Pacific Pediatric Cardiology — Victorville, CA
Parakeet Health — San Francisco, CA
PathoGene, Inc. — Monrovia, CA
PATHOMIQ, Inc. — Cupertino, CA
PEDIATRIC HEALTH AND WELLNESS — Rocklin, CA
Pediatrics Technologies — San Francisco, CA
Plinth Analytics — New York, NY
Senphonix — Saint Paul, MN
VERY | Virtual Eating Recovery for You — Denver, CA
CareAtlas Inc — Austin, TX
DigiBite Dental — Philadelphia
FYR Bio — Missoula, MT

Profile updated Jul 29, 2026. Sources: orbits-oncology.com, app.orbits-oncology.com